HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bed Bath & Beyond ‘Spyware’ Violates Pennsylvania Wiretap Act – Class Action Complaint

Executive Summary

Visitors to BB&B’s website were not informed and did not consent to its session replay “spyware,” which tracks how consumers interact with the site, “their mouse movements and clicks, keystrokes, search terms, information inputted into the website, and pages and content viewed,” the plaintiff says.

You may also be interested in...



FDA’s Linda Katz Takes MoCRA Questions At IBA Regulatory Workshop

The director of FDA’s Office of Cosmetics and Colors addressed questions on the responsible person required by the Modernization of Cosmetics Regulations Act, safety substantiation, adverse event reporting and more at the IBA virtual event.

Cosmetics Europe Expanding To Meet Historic Challenges: ‘There’s Never Been A Time Like This’

Director-general John Chave discusses regulatory heavy-handedness in the EU, implications for animal testing, declining European investment, and Cosmetics Europe’s message to policymakers going into the 2024 EU elections and beyond.

Akili Turns Heel, Goes ‘All In’ On OTC Model For ADHD Digital Therapeutics

The Boston, MA-based company says the pivot away from Rx will enable it to pursue a significantly larger market and remove “key friction points” that have prevented patients from accessing its game-based digital ADHD treatment. The company is targeting year-over-year cost savings of $8m-$18m after investments to juice up its direct digital marketing program.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel